Vanguard Capital Management
ANIK icon

Vanguard Capital Management’s Anika Therapeutics ANIK Stock Holding History

Vanguard Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.37M Sell
572,113
-33,664
-6% -$499K ﹤0.01% 2923
2026
Q1 		$8.78M Buy
+605,777
New +$7.03M ﹤0.01% 2803

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Vanguard Capital Management's ANIK Position: Q2 2026 in Review

Vanguard Capital Management reduced its Anika Therapeutics (ANIK) stake by 5.6% in Q2 2026, selling an estimated $499K and leaving 572,113 shares worth $8.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

Vanguard Capital Management first reported a position in ANIK in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.78M in Q1 2026. 132 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Vanguard Capital Management held 572,113 shares of Anika Therapeutics worth $8.37M as of Q2 2026.
  • Vanguard Capital Management sold 33,664 Anika Therapeutics shares in Q2 2026, an estimated $499K.
  • Anika Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2923 holding.
  • Vanguard Capital Management first reported a position in Anika Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Anika Therapeutics position peaked at $8.78M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.